

Longchao Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8805858/publications.pdf>

Version: 2024-02-01

14
papers

736
citations

840776

11
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

1166
citing authors

#	ARTICLE	IF	CITATIONS
1	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. <i>Cell Reports Medicine</i> , 2022, 3, 100554.	6.5	29
2	Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. <i>Nature Cancer</i> , 2022, 3, 437-452.	13.2	19
3	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. <i>Cancer Cell</i> , 2021, 39, 96-108.e6.	16.8	153
4	The AIM2 and NLRP3 inflammasomes trigger IL-1 β -mediated antitumor effects during radiation. <i>Science Immunology</i> , 2021, 6, .	11.9	33
5	Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. <i>Nature Biomedical Engineering</i> , 2021, 5, 1261-1273.	22.5	32
6	AXL targeting with bemcentinib restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells. , 2021, 9, A632-A632.		0
7	Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1359-1371.	7.0	90
8	Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1 ^{int} Tim-3 ^{hi} CD8 ⁺ T cells. <i>JCI Insight</i> , 2020, 5, .	5.0	30
9	Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. <i>Science Immunology</i> , 2019, 4, .	11.9	30
10	T cell-derived lymphotoxin limits Th1 response during HSV-1 infection. <i>Scientific Reports</i> , 2018, 8, 17727.	3.3	7
11	Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. <i>Cell Reports</i> , 2018, 24, 2101-2111.	6.4	90
12	Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. <i>Hepatology</i> , 2017, 66, 1067-1082.	7.3	44
13	Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. <i>Journal of Immunology</i> , 2016, 196, 3079-3087.	0.8	69
14	A mouse model for HBV immunotolerance and immunotherapy. <i>Cellular and Molecular Immunology</i> , 2014, 11, 71-78.	10.5	110